However, in 2018, 8 cancer survivors who were treated with DeltaRex-G with or without DeltaVax, a tumor-targeted retrovector encoding a granulocyte macrophage colony stimulating factor (GM-CSF) gene, were reported (Liu et al., 2021). This evidence concerns the gene CSF2 and neoplasm.